Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADOR: Capsaicin in Digital Osteoarthritis
NCT06444919Phase 4
Key facts
- Status
- Recruiting
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Countries
- 1
- Modality
- Transdermal Patches, Small Molecules
- Drugs
- capsaicin 8% patch
- Conditions
- osteoarthritis (OA)neuropathic pain
01
Overview
Phase 4, randomised, double-blind trial of capsaicin 8% patch in osteoarthritis (OA) and neuropathic pain (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Intensity of pain in the fingers at Day 60. Started Mar 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Capsaicin 8%
Single application of Capsaicin 8% patch for 30 minutes
Capsaicin 0.04%
Single application of Capsaicin 0.04% patch (control) for 30 minutes
03
Who it enrols
Patients with digital osteoarthritis and neuropathic pain (DN4 >= 4/10, VAS >= 40mm) who have had an inadequate response to conventional analgesics and NSAIDs.
04
Endpoints
Primary
Intensity of pain in the fingers
Secondary
Functional disability
Functional index
Anxiety and depression
Painful symptoms of osteoarthritis
Treatment safety
Patient impression of change
Beyond the preview
Go deeper on NCT06444919.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444919.